{
  "name": "IRLAB Therapeutics",
  "slug": "irlab-therapeutics",
  "description": "Statiskt källarkiv med kurshistorik, finansiella rapporter och regulatoriska dokument. För nordiska bolag används Nasdaq Nordic primärt och MFN endast för saknade rapportperioder.",
  "status": "complete",
  "updated_at": "2026-08-07T04:27:38Z",
  "nasdaq_status": "retrieved",
  "latest_market": "2026-08-06: stängning 1.34, volym 160291",
  "mfn_status": "retrieved",
  "mfn_count": 1,
  "nasdaq_reports_status": "retrieved",
  "reports": {
    "available": true,
    "url": "/company/irlab-therapeutics/reports",
    "count": 16,
    "nasdaq_count": 16,
    "mfn_fallback_count": 0,
    "items": [
      {
        "report_key": "2026:q1",
        "period_label": "2026 Q1",
        "date": "2026-05-06",
        "title": "Kvartalsrapport Q1 2026",
        "original_title": "IRLAB publicerar delårsrapport för perioden januari - mars 2026",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=bac2e7970971b6dee153f44604e4bfd08&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2026,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
            "title": "Kvartalsrapport Q1 2026",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a87c6b7713f581fc9283b5b380be76ca6",
            "date": "2026-05-06",
            "period": "2026-q1",
            "form_type": "interim-report",
            "report_key": "2026:q1",
            "filename": "IRLAB_Q1_2026_SWE_Final.pdf",
            "text_chars": 64339,
            "sha256": "505b54a29eaa6a93bf41402ed03679fe073606a2cd013d7c22f34f3f8c322dd5",
            "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
            "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
                "chars": 64339
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:annual",
        "period_label": "2025 Årsredovisning",
        "date": "2026-04-29",
        "title": "Årsredovisning 2025",
        "original_title": "IRLAB publicerar årsredovisning för 2025",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=baa536c9dcacc3328fe02db5b0797b2c0&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2025,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2025",
            "title": "Årsredovisning 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a08f90ae9f03475896d18a02f6d5b699a",
            "date": "2026-04-29",
            "period": "2025-annual",
            "form_type": "annual-report",
            "report_key": "2025:annual",
            "filename": "IRLAB_AR_2025_Final.pdf",
            "text_chars": 305823,
            "sha256": "b398d00744eb567bb06f1835db007e9b595168a464cf4dce9f6d11f192e85b88",
            "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2025",
            "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2025",
            "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
                "chars": 173738
              },
              {
                "number": 2,
                "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
                "chars": 132083
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q4",
        "period_label": "2025 Q4",
        "date": "2026-02-25",
        "title": "Kvartalsrapport Q4 2025",
        "original_title": "IRLAB publicerar delårsrapport för perioden januari - december 2025",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b3681710b0170c4d7a81e9bf501ddb949&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2025,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
            "title": "Kvartalsrapport Q4 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a48787c44f5366998963665e14d608ab4",
            "date": "2026-02-25",
            "period": "2025-q4",
            "form_type": "year-end-report",
            "report_key": "2025:q4",
            "filename": "IRLAB_Bokslutskommunike_2025_Janauri_December_SWE_FINAL.pdf",
            "text_chars": 66724,
            "sha256": "8917d995eeda295c1c407c7b77047790a2f1ba2ae93c17920902bb736a8bef8d",
            "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
            "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
                "chars": 66724
              }
            ]
          }
        ],
        "alternatives": [
          {
            "source": "MFN fallback",
            "language": "unknown",
            "title": "IRLAB publishes full-year report for the period January – December 2025",
            "release_url": "https://mfn.se/a/irlab-therapeutics/irlab-publishes-full-year-report-for-the-period-january-december-2025"
          }
        ]
      },
      {
        "report_key": "2025:q3",
        "period_label": "2025 Q3",
        "date": "2025-10-29",
        "title": "Kvartalsrapport Q3 2025",
        "original_title": "IRLAB publicerar delårsrapport för perioden januari - september 2025",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b7929cb4c562f8434dcd68ed2a24aa5eb&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
            "title": "Kvartalsrapport Q3 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a3ba9467d849249338ab8792cb61df4b3",
            "date": "2025-10-29",
            "period": "2025-q3",
            "form_type": "interim-report",
            "report_key": "2025:q3",
            "filename": "IRLAB_Q3_2025_SVE.pdf",
            "text_chars": 64430,
            "sha256": "928ee49df5c30450024cec6bdc2270377b083d96c0a99d932cacadee38b4e448",
            "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
            "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
                "chars": 64430
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q2",
        "period_label": "2025 Q2",
        "date": "2025-08-27",
        "title": "Kvartalsrapport Q2 2025",
        "original_title": "IRLAB publicerar delårsrapport för perioden januari - juni 2025",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b3ead9f8ea853de98bb4a89098c78b2e8&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
            "title": "Kvartalsrapport Q2 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a31d3ebef0648ca7e0eeb33d8e7266b8b",
            "date": "2025-08-27",
            "period": "2025-q2",
            "form_type": "interim-report",
            "report_key": "2025:q2",
            "filename": "IRLAB_Q2_FINAL_SE.pdf",
            "text_chars": 60171,
            "sha256": "03c14f5469d2b82ba9f7cf702eac7ad9c91f0bee2d0a9de930f2dc7d58199329",
            "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
            "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
                "chars": 60171
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2025:q1",
        "period_label": "2025 Q1",
        "date": "2025-05-07",
        "title": "Kvartalsrapport Q1 2025",
        "original_title": "IRLAB publicerar delårsrapport för perioden januari - mars 2025",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b4dbcd7fac0277fe4ff017a6db8554524&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2025,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
            "title": "Kvartalsrapport Q1 2025",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a1f353db402d76b5479bf0040f1c3cce6",
            "date": "2025-05-07",
            "period": "2025-q1",
            "form_type": "interim-report",
            "report_key": "2025:q1",
            "filename": "IRLAB_Q1_FINAL_SE.pdf",
            "text_chars": 59022,
            "sha256": "5ac7796a165c826ffb3920a3b34fb66ee08a1033afdbd750f5536ef4e1a5f478",
            "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
            "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
                "chars": 59022
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:annual",
        "period_label": "2024 Årsredovisning",
        "date": "2025-04-25",
        "title": "Årsredovisning 2024",
        "original_title": "IRLAB publicerar årsredovisning för 2024",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b6333f0fe3eb45a89c1a0c519e8add71a&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2024,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2024",
            "title": "Årsredovisning 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ac4a1932700de0a546597011645bdf448",
            "date": "2025-04-25",
            "period": "2024-annual",
            "form_type": "annual-report",
            "report_key": "2024:annual",
            "filename": "IRLAB_Arsredovisning_2025_Lowres.pdf",
            "text_chars": 290897,
            "sha256": "bc8fcbfb01a527e6bdd643048fa5dbe5dd3801df7ba92c594be73d58c1254748",
            "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2024",
            "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2024",
            "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
                "chars": 173259
              },
              {
                "number": 2,
                "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
                "chars": 117636
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q4",
        "period_label": "2024 Q4",
        "date": "2025-02-12",
        "title": "Kvartalsrapport Q4 2024",
        "original_title": "IRLAB publicerar bokslutskommuniké för 2024",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b62c405c57bf2b81dac0fd7ccc752fdaa&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2024,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
            "title": "Kvartalsrapport Q4 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/ac65fdb073394f8e0661529ce41b2a0d3",
            "date": "2025-02-12",
            "period": "2024-q4",
            "form_type": "year-end-report",
            "report_key": "2024:q4",
            "filename": "IRLAB_Q4_SVE_2025_02_12.pdf",
            "text_chars": 59877,
            "sha256": "cf9867387056374714f0d929e163622e53c4d747347a02e5ba4a70675520bc10",
            "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
            "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
                "chars": 59877
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q3",
        "period_label": "2024 Q3",
        "date": "2024-10-30",
        "title": "Kvartalsrapport Q3 2024",
        "original_title": "IRLAB publicerar delårsrapport för perioden januari - september 2024",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b75f15362c96e9c2427dcba54fa88f2c9&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
            "title": "Kvartalsrapport Q3 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/aa88601b14548120afa4692d054312648",
            "date": "2024-10-30",
            "period": "2024-q3",
            "form_type": "interim-report",
            "report_key": "2024:q3",
            "filename": "IRLAB_Q3_2024_SVE.pdf",
            "text_chars": 61821,
            "sha256": "c7a90c457983af2c8fc9db92d1c51ddf7ebc39a3d34568046704eecbcfaec9f8",
            "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
            "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
                "chars": 61821
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q2",
        "period_label": "2024 Q2",
        "date": "2024-07-10",
        "title": "Kvartalsrapport Q2 2024",
        "original_title": "IRLAB publicerar delårsrapport för perioden januari-juni 2024",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b1a932c7e411d1522abffc928eb926ea1&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
            "title": "Kvartalsrapport Q2 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a8fe2f4726a5dbc7f4f772724efc021d6",
            "date": "2024-07-10",
            "period": "2024-q2",
            "form_type": "interim-report",
            "report_key": "2024:q2",
            "filename": "IRLAB_Q2_2024_SVE.pdf",
            "text_chars": 54432,
            "sha256": "7261d5991584403d422756691cb5fae45edb9e4dc2010a530f649262f8534780",
            "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
            "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
                "chars": 54432
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2024:q1",
        "period_label": "2024 Q1",
        "date": "2024-05-08",
        "title": "Kvartalsrapport Q1 2024",
        "original_title": "IRLAB publicerar delårsrapport för perioden januari-mars 2024",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b382108fa4f0ea3918dfb1ad2b2086216&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2024,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
            "title": "Kvartalsrapport Q1 2024",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a283d252335a38071c82196bacb1f08ba",
            "date": "2024-05-08",
            "period": "2024-q1",
            "form_type": "interim-report",
            "report_key": "2024:q1",
            "filename": "IRLAB_Q1_24_Final_SVE.pdf",
            "text_chars": 53733,
            "sha256": "fe521fb4271cf01c8b83263caf2e6ff835645a69ac731cbe1acad4a4d65ab8a0",
            "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
            "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
                "chars": 53733
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:annual",
        "period_label": "2023 Årsredovisning",
        "date": "2024-04-29",
        "title": "Årsredovisning 2023",
        "original_title": "IRLAB publicerar årsredovisning för 2023",
        "category": "Bokslut och Verksamhetsberättelse",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b2faf8be30c856129c7430454064a4244&lang=sv&src=listed",
        "language": "sv",
        "report_type": "annual-report",
        "fiscal_year": 2023,
        "quarter": "annual",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-arsredovisning-2023",
            "title": "Årsredovisning 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a680177f5f7902bb9c2b64c8ac8783bcc",
            "date": "2024-04-29",
            "period": "2023-annual",
            "form_type": "annual-report",
            "report_key": "2023:annual",
            "filename": "IRLAB_Arsredovisning_2023.pdf",
            "text_chars": 288962,
            "sha256": "8376ba43757e9f2515a2cb30dca7357684e494cf3ba8e5bc3bceb1784e900be5",
            "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2023",
            "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2023",
            "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
                "chars": 178416
              },
              {
                "number": 2,
                "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
                "chars": 110544
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q4",
        "period_label": "2023 Q4",
        "date": "2024-02-07",
        "title": "Kvartalsrapport Q4 2023",
        "original_title": "IRLAB publicerar bokslutskommuniké för perioden januari-december 2023",
        "category": "Bokslutskommuniké",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b8b3bfc3c4952ac57e1edd96aff953504&lang=sv&src=listed",
        "language": "sv",
        "report_type": "year-end-report",
        "fiscal_year": 2023,
        "quarter": "q4",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
            "title": "Kvartalsrapport Q4 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/adda82490b9cd45873daa2c13d1a42a2f",
            "date": "2024-02-07",
            "period": "2023-q4",
            "form_type": "year-end-report",
            "report_key": "2023:q4",
            "filename": "IRLAB_Bokslutskommunike_2023.pdf",
            "text_chars": 56219,
            "sha256": "909162dbd9614fee71d5e70483759de69c87753a4fb3c235a0008e0f84bb31eb",
            "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
            "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
                "chars": 56219
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q3",
        "period_label": "2023 Q3",
        "date": "2023-10-25",
        "title": "Kvartalsrapport Q3 2023",
        "original_title": "IRLAB publicerar delårsrapport för perioden januari-september 2023",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b437a375968b71a74800487bc89143c8d&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q3",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
            "title": "Kvartalsrapport Q3 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a9a35737af26033f7b36b6809e73cb2f5",
            "date": "2023-10-25",
            "period": "2023-q3",
            "form_type": "interim-report",
            "report_key": "2023:q3",
            "filename": "IRLAB_Delarsrapport_Q3_2023.pdf",
            "text_chars": 54885,
            "sha256": "618eb6cb64f39e88e7d435f572de1f79e8103b1f7ee2a9f3dd48042ccdef06e3",
            "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
            "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
                "chars": 54885
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q2",
        "period_label": "2023 Q2",
        "date": "2023-08-30",
        "title": "Kvartalsrapport Q2 2023",
        "original_title": "IRLAB publicerar delårsrapport för perioden januari-juni 2023",
        "category": "Halvårsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b4a1cd1568099a10abdbf6b456e09cec4&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q2",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
            "title": "Kvartalsrapport Q2 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a06944ca44a858fbd57afb56e67641dcc",
            "date": "2023-08-30",
            "period": "2023-q2",
            "form_type": "interim-report",
            "report_key": "2023:q2",
            "filename": "IRLAB_Delarsrapport_Q2_2023.pdf",
            "text_chars": 56836,
            "sha256": "d658b6246c4a52f07c9bdd58ef5155ff9c73f18772353d15b5511f82599d5395",
            "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
            "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
                "chars": 56836
              }
            ]
          }
        ],
        "alternatives": []
      },
      {
        "report_key": "2023:q1",
        "period_label": "2023 Q1",
        "date": "2023-05-10",
        "title": "Kvartalsrapport Q1 2023",
        "original_title": "IRLAB publicerar delårsrapport för perioden januari-mars 2023",
        "category": "Interimsrapport",
        "source": "Nasdaq Nordic",
        "source_class": "nasdaq-report",
        "source_url": "https://view.news.eu.nasdaq.com/view?id=b47ae27d3a5657ed942eee368ce3a4c0f&lang=sv&src=listed",
        "language": "sv",
        "report_type": "interim-report",
        "fiscal_year": 2023,
        "quarter": "q1",
        "documents": [
          {
            "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
            "title": "Kvartalsrapport Q1 2023",
            "source": "Nasdaq Nordic",
            "source_class": "nasdaq-report",
            "source_url": "https://attachment.news.eu.nasdaq.com/a35f1abb0bd3293f977d871a5c05f21b9",
            "date": "2023-05-10",
            "period": "2023-q1",
            "form_type": "interim-report",
            "report_key": "2023:q1",
            "filename": "IRLAB_Delarsrapport_Q1_2023.pdf",
            "text_chars": 65900,
            "sha256": "1dc1c34123f46504928637e587beda0a970ed7ff02c96aed652de0bbde749a2a",
            "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
            "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
            "parts": [
              {
                "number": 1,
                "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
                "chars": 65900
              }
            ]
          }
        ],
        "alternatives": []
      }
    ]
  },
  "report_count": 16,
  "nasdaq_report_count": 16,
  "mfn_fallback_count": 0,
  "sec_status": "skipped",
  "sec_count": 0,
  "fi_status": "retrieved",
  "fi_summary": {
    "company": "IRLAB Therapeutics",
    "identity": {
      "issuer": "Elicera Therapeutics AB",
      "lei": "549300I35L0R4INBFG27",
      "source": "FI aggregerade blankningspositioner",
      "row_count": 14,
      "score": 50.0,
      "status": "resolved",
      "requested_company": "IRLAB Therapeutics",
      "query": "Elicera Therapeutics AB",
      "candidate_count": 345
    },
    "period": {
      "from": "2024-08-07",
      "to": "2026-08-07",
      "years": 2
    },
    "generated_at": "2026-08-07T04:27:38Z",
    "insider": {
      "transactions": 13,
      "all_export_rows": 13,
      "acquisitions": 1,
      "disposals": 4,
      "other": 8,
      "acquisition_value_sek": 9000.0,
      "disposal_value_sek": 2471825.0,
      "characters": {
        "Avyttring": 4,
        "Förvärv": 1,
        "Lån mottaget": 1,
        "Teckning": 7
      }
    },
    "short_selling": {
      "aggregate_percent": 0.11,
      "current_public_positions": 0,
      "historical_changes": 9,
      "current_position_sum_over_0_5": 0
    },
    "sources": {
      "insider_register": "https://www.fi.se/sv/vara-register/insynsregistret/",
      "short_register": "https://www.fi.se/sv/vara-register/blankningsregistret/"
    }
  },
  "warnings": [],
  "source_identity": {
    "nasdaq_reports": {
      "slug": "",
      "instrument_id": "TX2308898",
      "resolved_url": "https://www.nasdaq.com/european-market-activity/shares/irlab-a?id=TX2308898"
    },
    "mfn": {
      "status": "resolved",
      "company_name": "IRLAB Therapeutics",
      "expected_name": "IRLAB Therapeutics",
      "match_score": 100.0,
      "slug": "irlab-therapeutics",
      "url": "https://mfn.se/all/a/irlab-therapeutics",
      "metadata": {
        "country": "Sverige",
        "list": "Small Cap Stockholm",
        "sector": "Hälsovård",
        "industry": "Bioteknik",
        "website": "https://irlab.se/"
      },
      "ticker_candidates": [],
      "attempts": []
    },
    "sec": null,
    "nasdaq": {
      "instrument_id": "TX2308898",
      "asset_class": "SHARES",
      "isin": "SE0012675361",
      "symbol": "IRLAB A",
      "company": "IRLAB Therapeutics A",
      "market": null,
      "last_sale_price": "SEK 1.34",
      "time_as_of": "2026-08-06"
    },
    "finansinspektionen": {
      "issuer": "Elicera Therapeutics AB",
      "lei": "549300I35L0R4INBFG27",
      "source": "FI aggregerade blankningspositioner",
      "row_count": 14,
      "score": 50.0,
      "status": "resolved",
      "requested_company": "IRLAB Therapeutics",
      "query": "Elicera Therapeutics AB",
      "candidate_count": 345
    }
  },
  "documents": [
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2026",
      "title": "Kvartalsrapport Q1 2026",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a87c6b7713f581fc9283b5b380be76ca6",
      "date": "2026-05-06",
      "period": "2026-q1",
      "form_type": "interim-report",
      "report_key": "2026:q1",
      "filename": "IRLAB_Q1_2026_SWE_Final.pdf",
      "text_chars": 64339,
      "sha256": "505b54a29eaa6a93bf41402ed03679fe073606a2cd013d7c22f34f3f8c322dd5",
      "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026",
      "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2026/part-001.html",
          "chars": 64339
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2025",
      "title": "Årsredovisning 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a08f90ae9f03475896d18a02f6d5b699a",
      "date": "2026-04-29",
      "period": "2025-annual",
      "form_type": "annual-report",
      "report_key": "2025:annual",
      "filename": "IRLAB_AR_2025_Final.pdf",
      "text_chars": 305823,
      "sha256": "b398d00744eb567bb06f1835db007e9b595168a464cf4dce9f6d11f192e85b88",
      "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2025",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2025",
      "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/part-001.html",
          "chars": 173738
        },
        {
          "number": 2,
          "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2025/part-002.html",
          "chars": 132083
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2025",
      "title": "Kvartalsrapport Q4 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a48787c44f5366998963665e14d608ab4",
      "date": "2026-02-25",
      "period": "2025-q4",
      "form_type": "year-end-report",
      "report_key": "2025:q4",
      "filename": "IRLAB_Bokslutskommunike_2025_Janauri_December_SWE_FINAL.pdf",
      "text_chars": 66724,
      "sha256": "8917d995eeda295c1c407c7b77047790a2f1ba2ae93c17920902bb736a8bef8d",
      "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025",
      "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2025/part-001.html",
          "chars": 66724
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2025",
      "title": "Kvartalsrapport Q3 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a3ba9467d849249338ab8792cb61df4b3",
      "date": "2025-10-29",
      "period": "2025-q3",
      "form_type": "interim-report",
      "report_key": "2025:q3",
      "filename": "IRLAB_Q3_2025_SVE.pdf",
      "text_chars": 64430,
      "sha256": "928ee49df5c30450024cec6bdc2270377b083d96c0a99d932cacadee38b4e448",
      "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025",
      "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2025/part-001.html",
          "chars": 64430
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2025",
      "title": "Kvartalsrapport Q2 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a31d3ebef0648ca7e0eeb33d8e7266b8b",
      "date": "2025-08-27",
      "period": "2025-q2",
      "form_type": "interim-report",
      "report_key": "2025:q2",
      "filename": "IRLAB_Q2_FINAL_SE.pdf",
      "text_chars": 60171,
      "sha256": "03c14f5469d2b82ba9f7cf702eac7ad9c91f0bee2d0a9de930f2dc7d58199329",
      "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025",
      "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2025/part-001.html",
          "chars": 60171
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2025",
      "title": "Kvartalsrapport Q1 2025",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a1f353db402d76b5479bf0040f1c3cce6",
      "date": "2025-05-07",
      "period": "2025-q1",
      "form_type": "interim-report",
      "report_key": "2025:q1",
      "filename": "IRLAB_Q1_FINAL_SE.pdf",
      "text_chars": 59022,
      "sha256": "5ac7796a165c826ffb3920a3b34fb66ee08a1033afdbd750f5536ef4e1a5f478",
      "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025",
      "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2025/part-001.html",
          "chars": 59022
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2024",
      "title": "Årsredovisning 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ac4a1932700de0a546597011645bdf448",
      "date": "2025-04-25",
      "period": "2024-annual",
      "form_type": "annual-report",
      "report_key": "2024:annual",
      "filename": "IRLAB_Arsredovisning_2025_Lowres.pdf",
      "text_chars": 290897,
      "sha256": "bc8fcbfb01a527e6bdd643048fa5dbe5dd3801df7ba92c594be73d58c1254748",
      "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2024",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2024",
      "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/part-001.html",
          "chars": 173259
        },
        {
          "number": 2,
          "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2024/part-002.html",
          "chars": 117636
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2024",
      "title": "Kvartalsrapport Q4 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/ac65fdb073394f8e0661529ce41b2a0d3",
      "date": "2025-02-12",
      "period": "2024-q4",
      "form_type": "year-end-report",
      "report_key": "2024:q4",
      "filename": "IRLAB_Q4_SVE_2025_02_12.pdf",
      "text_chars": 59877,
      "sha256": "cf9867387056374714f0d929e163622e53c4d747347a02e5ba4a70675520bc10",
      "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024",
      "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2024/part-001.html",
          "chars": 59877
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2024",
      "title": "Kvartalsrapport Q3 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/aa88601b14548120afa4692d054312648",
      "date": "2024-10-30",
      "period": "2024-q3",
      "form_type": "interim-report",
      "report_key": "2024:q3",
      "filename": "IRLAB_Q3_2024_SVE.pdf",
      "text_chars": 61821,
      "sha256": "c7a90c457983af2c8fc9db92d1c51ddf7ebc39a3d34568046704eecbcfaec9f8",
      "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024",
      "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2024/part-001.html",
          "chars": 61821
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2024",
      "title": "Kvartalsrapport Q2 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a8fe2f4726a5dbc7f4f772724efc021d6",
      "date": "2024-07-10",
      "period": "2024-q2",
      "form_type": "interim-report",
      "report_key": "2024:q2",
      "filename": "IRLAB_Q2_2024_SVE.pdf",
      "text_chars": 54432,
      "sha256": "7261d5991584403d422756691cb5fae45edb9e4dc2010a530f649262f8534780",
      "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024",
      "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2024/part-001.html",
          "chars": 54432
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2024",
      "title": "Kvartalsrapport Q1 2024",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a283d252335a38071c82196bacb1f08ba",
      "date": "2024-05-08",
      "period": "2024-q1",
      "form_type": "interim-report",
      "report_key": "2024:q1",
      "filename": "IRLAB_Q1_24_Final_SVE.pdf",
      "text_chars": 53733,
      "sha256": "fe521fb4271cf01c8b83263caf2e6ff835645a69ac731cbe1acad4a4d65ab8a0",
      "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024",
      "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2024/part-001.html",
          "chars": 53733
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-arsredovisning-2023",
      "title": "Årsredovisning 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a680177f5f7902bb9c2b64c8ac8783bcc",
      "date": "2024-04-29",
      "period": "2023-annual",
      "form_type": "annual-report",
      "report_key": "2023:annual",
      "filename": "IRLAB_Arsredovisning_2023.pdf",
      "text_chars": 288962,
      "sha256": "8376ba43757e9f2515a2cb30dca7357684e494cf3ba8e5bc3bceb1784e900be5",
      "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2023",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2023",
      "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/part-001.html",
          "chars": 178416
        },
        {
          "number": 2,
          "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-arsredovisning-2023/part-002.html",
          "chars": 110544
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q4-2023",
      "title": "Kvartalsrapport Q4 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/adda82490b9cd45873daa2c13d1a42a2f",
      "date": "2024-02-07",
      "period": "2023-q4",
      "form_type": "year-end-report",
      "report_key": "2023:q4",
      "filename": "IRLAB_Bokslutskommunike_2023.pdf",
      "text_chars": 56219,
      "sha256": "909162dbd9614fee71d5e70483759de69c87753a4fb3c235a0008e0f84bb31eb",
      "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023",
      "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q4-2023/part-001.html",
          "chars": 56219
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q3-2023",
      "title": "Kvartalsrapport Q3 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a9a35737af26033f7b36b6809e73cb2f5",
      "date": "2023-10-25",
      "period": "2023-q3",
      "form_type": "interim-report",
      "report_key": "2023:q3",
      "filename": "IRLAB_Delarsrapport_Q3_2023.pdf",
      "text_chars": 54885,
      "sha256": "618eb6cb64f39e88e7d435f572de1f79e8103b1f7ee2a9f3dd48042ccdef06e3",
      "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023",
      "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q3-2023/part-001.html",
          "chars": 54885
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q2-2023",
      "title": "Kvartalsrapport Q2 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a06944ca44a858fbd57afb56e67641dcc",
      "date": "2023-08-30",
      "period": "2023-q2",
      "form_type": "interim-report",
      "report_key": "2023:q2",
      "filename": "IRLAB_Delarsrapport_Q2_2023.pdf",
      "text_chars": 56836,
      "sha256": "d658b6246c4a52f07c9bdd58ef5155ff9c73f18772353d15b5511f82599d5395",
      "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023",
      "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q2-2023/part-001.html",
          "chars": 56836
        }
      ]
    },
    {
      "doc_id": "nasdaq-nordic-kvartalsrapport-q1-2023",
      "title": "Kvartalsrapport Q1 2023",
      "source": "Nasdaq Nordic",
      "source_class": "nasdaq-report",
      "source_url": "https://attachment.news.eu.nasdaq.com/a35f1abb0bd3293f977d871a5c05f21b9",
      "date": "2023-05-10",
      "period": "2023-q1",
      "form_type": "interim-report",
      "report_key": "2023:q1",
      "filename": "IRLAB_Delarsrapport_Q1_2023.pdf",
      "text_chars": 65900,
      "sha256": "1dc1c34123f46504928637e587beda0a970ed7ff02c96aed652de0bbde749a2a",
      "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023",
      "txt_url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/irlab-therapeutics/documents/nasdaq-nordic-kvartalsrapport-q1-2023/part-001.html",
          "chars": 65900
        }
      ]
    },
    {
      "doc_id": "mfn-mfn-bolagssida-och-bolagsmetadata",
      "title": "MFN bolagssida och bolagsmetadata",
      "source": "MFN",
      "source_class": "mfn",
      "source_url": "https://mfn.se/all/a/irlab-therapeutics",
      "date": null,
      "period": null,
      "form_type": "company-page",
      "report_key": null,
      "filename": "company.txt",
      "text_chars": 12861,
      "sha256": "04f334cc5c71867ede296ccddb4d0d58ccbb3892324592c834b595095590ff0e",
      "url": "/company/irlab-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata",
      "txt_url": "/company/irlab-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "absolute_txt_url": "https://spela.port0.org/company/irlab-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata/fulltext.txt",
      "parts": [
        {
          "number": 1,
          "url": "/company/irlab-therapeutics/documents/mfn-mfn-bolagssida-och-bolagsmetadata/part-001.html",
          "chars": 12861
        }
      ]
    }
  ],
  "market_files": [
    {
      "label": "Nasdaq kurshistorik CSV",
      "url": "/company/irlab-therapeutics/market/history.csv",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/market/history.csv"
    },
    {
      "label": "Nasdaq kurshistorik JSON",
      "url": "/company/irlab-therapeutics/market/history.json",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/market/history.json"
    },
    {
      "label": "Nasdaq manifest JSON",
      "url": "/company/irlab-therapeutics/market/manifest.json",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/market/manifest.json"
    },
    {
      "label": "Nasdaq instrumentidentitet JSON",
      "url": "/company/irlab-therapeutics/market/instrument.json",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/market/instrument.json"
    },
    {
      "label": "MFN manifest JSON",
      "url": "/company/irlab-therapeutics/market/mfn-manifest.json",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/market/mfn-manifest.json"
    },
    {
      "label": "Nasdaq rapportmanifest JSON",
      "url": "/company/irlab-therapeutics/market/nasdaq-reports-manifest.json",
      "absolute_url": "https://spela.port0.org/company/irlab-therapeutics/market/nasdaq-reports-manifest.json"
    }
  ],
  "sec_facts": {
    "status": "missing",
    "metrics": []
  },
  "morningstar": {
    "configured": false,
    "status": "inte hämtad",
    "captured_at": null,
    "view_count": 0,
    "url": "/company/irlab-therapeutics/morningstar"
  },
  "finansinspektionen": {
    "available": true,
    "status": "retrieved",
    "url": "/company/irlab-therapeutics/finansinspektionen",
    "transaction_count": 13,
    "aggregate_short_percent": 0.11,
    "files": [
      {
        "filename": "summary.json",
        "label": "Sammanfattning JSON",
        "url": "summary.json"
      },
      {
        "filename": "insider-transactions.csv",
        "label": "Insynstransaktioner CSV",
        "url": "insider-transactions.csv"
      },
      {
        "filename": "insider-transactions.json",
        "label": "Insynstransaktioner JSON",
        "url": "insider-transactions.json"
      },
      {
        "filename": "short-current.json",
        "label": "Aktuella blankningspositioner JSON",
        "url": "short-current.json"
      },
      {
        "filename": "short-history.json",
        "label": "Historiska blankningspositioner JSON",
        "url": "short-history.json"
      },
      {
        "filename": "short-aggregate.json",
        "label": "Aggregerad blankning JSON",
        "url": "short-aggregate.json"
      },
      {
        "filename": "manifest.json",
        "label": "Hämtningsmanifest JSON",
        "url": "manifest.json"
      }
    ]
  },
  "llms_url": "/company/irlab-therapeutics/llms.txt",
  "json_url": "/company/irlab-therapeutics/company.json",
  "document_index_url": "/company/irlab-therapeutics/documents.json",
  "absolute_url": "https://spela.port0.org/company/irlab-therapeutics"
}